000168826 001__ 168826
000168826 005__ 20240229133618.0
000168826 0247_ $$2doi$$a10.1002/hep.31902
000168826 0247_ $$2pmid$$apmid:33991110
000168826 0247_ $$2ISSN$$a0270-9139
000168826 0247_ $$2ISSN$$a1527-3350
000168826 0247_ $$2altmetric$$aaltmetric:105930769
000168826 037__ $$aDKFZ-2021-01077
000168826 041__ $$aEnglish
000168826 082__ $$a610
000168826 1001_ $$0P:(DE-He78)e4d7c2f391da716edc9beec6468f108f$$aRiedl, Tobias$$b0$$eFirst author$$udkfz
000168826 245__ $$aHIF1α-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
000168826 260__ $$aNew York [u.a.]$$bWiley Interscience$$c2021
000168826 3367_ $$2DRIVER$$aarticle
000168826 3367_ $$2DataCite$$aOutput Types/Journal article
000168826 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634305349_1829
000168826 3367_ $$2BibTeX$$aARTICLE
000168826 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168826 3367_ $$00$$2EndNote$$aJournal Article
000168826 500__ $$a#EA:F180#LA:F180# / 2021 Oct;74(4):1766-1781
000168826 520__ $$aNew therapeutic strategies against Hepatitis B virus (HBV) focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia inducible factor 1 alpha (HIF1α) stabilisation has been associated with impaired immune responses. HBV pathogenesis triggers chronic hepatitis-related scaring, leading inter alia to modulation of liver oxygenation and transient immune activation, both factors playing a role in HIF1α stabilisation. We addressed whether HIF1α interferes with immune-mediated induction of the cytidine deaminase APOBEC3B and subsequent covalently closed circular DNA (cccDNA) decay. Liver biopsies of chronic HBV patients (CHB) were analysed by IHC, and in situ hybridization. The effect of HIF1α induction/stabilisation on differentiated HepaRG or mice +/- HBV +/- LTβR-agonist (BS1) was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analysed by RT-qPCR, immunoblotting, ChIP, ICC, and mass-spectrometry. Analysing CHB highlighted that areas with high HIF1α levels and low A3B expression correlated with high HBcAg, potentially representing a reservoir for HBV survival in immune-active patients. In vitro, HIF1α stabilisation, strongly impaired A3B expression and anti-HBV effect. Interestingly, HIF1α knock-down was sufficient to rescue the inhibition of A3B-upregulation and -mediated antiviral effects, whereas HIF2α knock-down had no effect. HIF1α stabilisation decreased the level of RelB protein but not its mRNA, which was confirmed in vivo. Noteworthy, this function of HIF1α was independent of its partner ARNT. In conclusion, inhibiting HIF1α expression or stabilisation represents a novel anti-HBV strategy in the context of immune-mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo, and should be considered as a restricting factor in the development of novel immune therapies.
000168826 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000168826 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168826 650_7 $$2Other$$aHIF1α
000168826 650_7 $$2Other$$aHepatitis B virus
000168826 650_7 $$2Other$$aNF-κB
000168826 650_7 $$2Other$$acccDNA
000168826 650_7 $$2Other$$areservoir
000168826 7001_ $$0P:(DE-He78)cba564af7ad8b1c41cd1f9f8410896e5$$aFaure-Dupuy, Suzanne$$b1$$udkfz
000168826 7001_ $$aRolland, Maude$$b2
000168826 7001_ $$0P:(DE-HGF)0$$aSchuehle, Svenja$$b3
000168826 7001_ $$aHizir, Zohier$$b4
000168826 7001_ $$0P:(DE-He78)b5d9469407737829d5348adb615655c6$$aCalderazzo, Silvia$$b5$$udkfz
000168826 7001_ $$aZhuang, Xiaodong$$b6
000168826 7001_ $$aWettengel, Jochen$$b7
000168826 7001_ $$aLopez, Martin Alexander$$b8
000168826 7001_ $$aBarnault, Romain$$b9
000168826 7001_ $$aMirakaj, Valbona$$b10
000168826 7001_ $$0P:(DE-He78)3c6157a315192b4a95e0138399b89da9$$aProkosch, Sandra$$b11$$udkfz
000168826 7001_ $$0P:(DE-He78)92c93319837b4b915db8393795faf0b6$$aHeide, Danijela$$b12$$udkfz
000168826 7001_ $$0P:(DE-HGF)0$$aLeuchtenbergeg, Corinna$$b13
000168826 7001_ $$0P:(DE-He78)0d37cc734b95fed555f2244d6fee6320$$aSchneider, Martin$$b14$$udkfz
000168826 7001_ $$0P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75$$aHeßling, Bernd$$b15
000168826 7001_ $$aStottmeier, Benjamin$$b16
000168826 7001_ $$aWessbecher, Isabel M$$b17
000168826 7001_ $$aSchirmacher, Peter$$b18
000168826 7001_ $$aMcKeating, Jane A$$b19
000168826 7001_ $$00000-0002-9421-1911$$aProtzer, Ulrike$$b20
000168826 7001_ $$00000-0002-9226-3419$$aDurantel, David$$b21
000168826 7001_ $$00000-0003-0482-7809$$aLucifora, Julie$$b22
000168826 7001_ $$aDejardin, Emmanuel$$b23
000168826 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b24$$eLast author$$udkfz
000168826 773__ $$0PERI:(DE-600)1472120-X$$a10.1002/hep.31902$$gp. hep.31902$$n4$$p1766-1781$$tHepatology$$v74$$x1527-3350$$y2021
000168826 909CO $$ooai:inrepo02.dkfz.de:168826$$pVDB
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e4d7c2f391da716edc9beec6468f108f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cba564af7ad8b1c41cd1f9f8410896e5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b5d9469407737829d5348adb615655c6$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3c6157a315192b4a95e0138399b89da9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92c93319837b4b915db8393795faf0b6$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0d37cc734b95fed555f2244d6fee6320$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000168826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000168826 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000168826 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000168826 9141_ $$y2021
000168826 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000168826 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-28$$wger
000168826 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEPATOLOGY : 2019$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000168826 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bHEPATOLOGY : 2019$$d2021-01-28
000168826 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lF180 Chronische Entzündung und Krebs$$x0
000168826 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000168826 9201_ $$0I:(DE-He78)W120-20160331$$kW120$$lW120 Proteinanalyse$$x2
000168826 980__ $$ajournal
000168826 980__ $$aVDB
000168826 980__ $$aI:(DE-He78)F180-20160331
000168826 980__ $$aI:(DE-He78)C060-20160331
000168826 980__ $$aI:(DE-He78)W120-20160331
000168826 980__ $$aUNRESTRICTED